| [1] |
Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: A modelling study[J]. Lancet Gastroenterol Hepatol, 2018, 3(6): 383-403. DOI: 10.1016/S2468-1253(18)30056-6. |
| [2] |
Chinese Society of Infectious Diseases, Chinese Medical Association, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007. |
| [3] |
HUANG DQ, LI X, LE MH, et al. Natural history and hepatocellular carcinoma risk in untreated chronic hepatitis B patients with indeterminate phase[J]. Clin Gastroenterol Hepatol, 2021. DOI: 10.1016/j.cgh.2021.01.019.[Onlineaheadofprint] |
| [4] |
ZHANG JQ, LI MM, QI XS, et al. An excerpt of update on prevention, diagnosis, and treatment and of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. J Clin Hepatol, 2018, 34(12): 2563-2567. DOI: 10.3969/j.issn.1001-5256.2018.12.011. |
| [5] |
YU YC, HOU JL. The highlights of EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection[J]. J Clin Hepatol, 2017, 33(6): 1017-1032. DOI: 10.3969/j.issn.1001-5256.2017.06.002. |
| [6] |
SARIN SK, KUMAR M, LAU GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: A 2015 update[J]. Hepatol Int, 2016, 10(1): 1-98. DOI: 10.1007/s12072-015-9675-4. |
| [7] |
YAO K, LIU J, WANG J, et al. Distribution and clinical characteristics of patients with chronic hepatitis B virus infection in the grey zone[J]. J Viral Hepat, 2021, 28(7): 1025-1033. DOI: 10.1111/jvh.13511. |
| [8] |
HSU YN, PAN CQ, ABBASI A, et al. Clinical presentation and disease phases of chronic hepatitis B using conventional versus modified ALT criteria in Asian Americans[J]. Dig Dis Sci, 2014, 59(4): 865-871. DOI: 10.1007/s10620-014-3054-1. |
| [9] |
CHOI GH, KIM GA, CHOI J, et al. High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation[J]. Aliment Pharmacol Ther, 2019, 50(2): 215-226. DOI: 10.1111/apt.15311. |
| [10] |
BONACCI M, LENS S, MARIÑO Z, et al. Anti-viral therapy can be delayed or avoided in a significant proportion of HBeAg-negative Caucasian patients in the Grey Zone[J]. Aliment Pharmacol Ther, 2018, 47(10): 1397-1408. DOI: 10.1111/apt.14613. |
DownLoad: